EGFR and non-small cell lung carcinoma: RCTs have highlighted the benefits of TKIs in EGFR-mutated NSCLC, with studies like LUX-Lung 3 and 6 showing improved PFS with afatinib compared to chemotherapy, even in patients with BMs [40].